The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting growing optimism in the orphan disease biotech sector, Goldman Sachs has initiated coverage on Stoke Therapeutics with a Buy rating and a $44 price target. The bullish stance is primarily driven by the potential of zorevunersen, with the bank projecting peak sales of $1.5 billion for the Dravet syndrome therapy. While the company missed revenue forecasts in its Q1-2026 earnings report, it successfully surpassed earnings per share (EPS) expectations.
This initiation comes as the biotechnology sector seeks fresh catalysts, with zorevunersen positioned as a potential first-of-its-kind disease-modifying therapy for Dravet syndrome, carrying an estimated 75% probability of success. Compared to industry peers, Stoke's proprietary technology for upregulating gene expression provides a competitive edge, justifying the significant premium implied by Goldman's target relative to current trading levels per market data.
According to market data, STOK shares closed at $31.38 on July 10, 2026, having traded between a low of $30.07 and a high of $33.02 during that session. Investors are now watching the $30.00 level as a key technical support following the analyst update. Looking ahead, broader market sentiment may be influenced by upcoming US ISM Services PMI data, which will provide insight into the economic environment for growth-oriented healthcare stocks.